 (CHEST 1998; 113:957-63) 
most widely used inhaler device. It has the advantages of being compact, portable, relatively cheap, and easy to use. However, many patients, especially children and the elderly, do not obtain optimal benefit because they fail to use (Boehringer Ingelheim) (Fig 1) is a novel, hand-held, multidose device that uses mechanical power from a spring rather than volatile gas propellants to release metered doses (15 p_L volume) of solutions for inhalation through a sophis¬ ticated system of nozzles.9 This generates a slow, gentle release of active substance over > 1 s with a high proportion of respirable particles. Because of the novel mechanism of aerosol generation and the qualities ofthe spray generated by RESPIMAT, the term "soft mist inhaler" has been coined as a generic term to describe the device.
The aims ofthe two randomized three-way crossover studies in healthy volunteers reported in this article were to examine, using gamma scintigraphy, the in vivo lung deposition of (1) the bronchodilator fenoterol and (2) the corticosteroid flunisolide following single-dose inhalation. Comparisons were made of the total and regional deposition of these drugs delivered by the new device, conventional MDIs, and MDIs with spacer devices. Furthermore, in the flunisolide study, the effect on lung deposition of a modification of the RESPIMAT by the addition of a baffle in the mouth¬ piece, designed to eliminate large, "nonrespirable" droplets from the spray, was investigated.
Materials and Methods

Subjects
In each of the two studies, 12 healthy male or nonpregnant female, nonsmoking volunteers aged between 18 and 65 years completed the study ( Table 4 and Figure 2 (bottom, b) Table 4 .
Adverse Events
There was no evidence in either study of any para¬ doxical bronchoconstriction in subjects receiving fenot-erol or flunisolide. This is an important observation since the formulations include either the preservative benzalkonium chloride or ethanolic solutions. FEVX values before and after dosing for each of the study regimens are shown in Table 5 . Otherwise reported adverse events in these studies were unremarkable and reflected the known effects of fenoterol and flunisolide.
One subject in the fenoterol study developed general¬ ized tremor immediately after dosing on two of the study days, accompanied by tachycardia on one occa¬ sion. Both events resolved spontaneously. 
